Tue 7/7/2020 01:54 ET
DJIA26287.03467.911.78%TELCO167.821.751.04%GOLD1783.093.030.17%Shanghai3384.4752.461.55%
S&P 5003179.7250.561.59%BANKS332.785.921.78%OIL40.340.290.72%BITCOIN9277.7745.460.49%
NASDAQ10433.65230.582.21%PHARM603.117.301.21%US/EU1.130.000.04%Futures3161.7510.120.32%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Diffusion Pharmaceuticals - DFFN   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DFFN
  
From: hunter1 (Rep: 469) reply to jvbbshepDate: 02/07/2020 09:22
Forum: Diffusion Pharmaceuticals - Msg #162Thread #674121826 (Rec: 0)
Re: News out - CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion ...

Nice news



any stock i buy or sell could be halted and go to zero at any time.if you can not lose it dont trade it.



Reply to jvbbshep - Msg #2815183 - 02/07/2020 08:38

News out - CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has been granted Patent Number EP2540696 B1 from the European Patent Office. This patent relates to pharmaceutical compositions of trans sodium crocetinate (“TSC”) and a cyclodextrin for use in therapy. Specifically claimed are TSC compositions are for use in conjunction with radiation or chemotherapy. Secondary claims relate to various compositions of TSC.
“The intellectual property described under our newly-granted European patent is quite broad and provides strong protection for our lead compound TSC,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. “This patent has claims to TSC compositions for use in therapy generally and has claims to compositions for use in treating brain cancer. We believe this patent not only improves the opportunity for partnerships in the GBM indication, it may improve the attractiveness of our lead compound by providing additional avenues for clinical development,” added Mr. Kalergis.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser hunter1: Reward | Watch | IgnoreDFFN: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DFFN
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.